Press Releases

Date Title and Summary View
March 21, 2018 Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has entered into a definitive agreement with several
View HTML
March 12, 2018 Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer
Eleven Biotherapeutics’ VISTA Trial of Vicinium™ in NMIBC On-Track for Topline Three-Month Data in Mid-2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies
View HTML
March 5, 2018 Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, president and chief executive
View HTML
February 8, 2018 Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
January 24, 2018 Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Richard F.
View HTML
January 2, 2018 Eleven Biotherapeutics to Present at Biotech Showcase 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
December 13, 2017 Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 13, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Dr.
View HTML
November 30, 2017 Eleven Biotherapeutics to Present at the LD Micro Main Event 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 30, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML
November 20, 2017 Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results
-- Phase 3 Enrollment on Track to Complete in Q1 2018 -- -- Topline 3-Month Data from Phase 3 Trial of Vicinium™ on Track for Mid-2018 -- -- Strengthened Balance Sheet with $8.0 million Capital Raise -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2017-- Eleven Biotherapeutics, Inc.
View HTML
November 9, 2017 Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will host a live conference call and webcast at
View HTML